Tetraphase Pharmaceuticals announced that the FDA has designated eravacycline, its lead antibiotic product as a Qualified Infectious Disease Product (QDIP) for complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI).

Eravacycline is being developed as a broad-spectrum IV and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant gram-negative infections.

Tetraphase is planning to advance eravacycline into Phase 3 clinical studies in cIAI and cUTI in the second half of this year.

For more information call (617) 715-3600 or visit www.tphase.com.